10:00AM – 10/1/2014: Partnering II @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London
Reporter: Aviva Lev-Ari, PhD, RN
Real Time Media Conference Coverage – Business and Scientific Channels by: https://pharmaceuticalintelligence.com
Co-Chaired by:
- Fintan Walton, CEO and Founder, PharmaVentures
– is it more expensive to auction?
– secrative negotiation, if successful, structure deal and terms to following – dynamics with uncertainty
- Stephanie Leousson, Principal, Torreya Partners
Panel is asked describe investment strategies
– new strategies: geographic, going public
– past: equity in IPO, at present long tern relations to offset costs, as the price will go up
10:00AM Partnering II – Deal Making: The Evolving Landscape of Deal Terms
- Carlos de Souza, Chief Business Officer, to-BBB
– Name chance to BBB Therapeutics, based in Netherland, BRAIN products, tumors, neural degeneration and MS.
– License or go to Public market
– partner need to bring a significant value, develop product in co-development – an alternative
– what type of deals will bering the recognition of value via selection of compaounds, win-win, cooperation and keeping the product in the pipelin
– small biotech clinical compounds and some pre-clinical: Plans to go to public market, requires years of preparation per schedule
- Corina Savill, Head BD&L Novartis Pharma AG
– trends: 7Billion in Acquisition, deals, BIOTECH high valuation in last two years, Private market has higher pricing
– Public Market Choices: acquisition by Big Pharma via IPO and then do a deal, Avista, geographic deal, win-win, Alphatech MAD,
– Auctioneering since 2006 and continue to do such deals, Israeli Gene company – Auctioneer, proportion equiyt, company reach the level that transplant and acquision will follow. Expensive technology to develop, take Equity position in the company using auctions allowing to materialize an acquisition CONDITIONED that the technology matures per plan, maturation involve continual innovation
– Aid in Dialysis had success with IPO, no auction, An osteoporosis company – decision not to pursue OP then invest took place no further integration Plans,
– Companies running Corporate investment portfolios: allowing collaboration, numeration drives to the sky,
– licensing becomes harder than in the past, due to availability of alternative avenues for investment
– Cash value is an opportunity, acquisition need to help the company investing
– In a geographic licensing it will become an acquisition target, PERIOD needed to absorb the positioning
- Lubor Gaal, Head of Europe Search & evaluation, Business Development BMS
– VCs some are very small following 2009, Deal to buy rather than integrate with development, staging acquision vs development of start ups — NEW landscape, late payment for VCs,
– both exist – Auctions of private companies
– first decision on Science then on Financials
– licensing and relationship: right ot compound given, the reason to acquire a company for additional value
– companies flourish NOT in the original plan they were created
- Luca Bolliger, VP and Group Licensing Director, RECORDATI S.A.
– In the 90s activity started, at present in 19 countries, integration PrimaryCare pursued by acquisition, move from PrimaryCare to become Global, risk profile across territories
– deals are not novelties, Upfront vs Royalties — not available to all companies, if you are not first in class less opportunity pools
- Philippe Lopes-Fernandes, Global Business Development, Merck Serono
– Outsourcing more that fully integration, NEW landscape smart decision are a must, sell alter is different than in the past — NO one can find the next Amgen
– Europe is the focus:
- Stuart Kay, Director Transactions, GlaxoSmithKline
– Access a network of connections, Source from Academia, run and manage is attractive, if not acquired, access to innovation can be yet maintained,
- QUESTION FROM THE AUDIENCE: Auction and Tax inversion any relations?
- no
#startup#science#partnerships#biotech
#venturecapital #pharmanews
|
@SachsAssociates@pharma_BI@BiotechNews |
Leave a Reply